Gonadorelin

Gonadorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) that stimulates the anterior pituitary to release endogenous LH and FSH. It became the primary alternative to HCG for fertility preservation during TRT after FDA restrictions on HCG compounding, and is now one of the most prescribed compounds in men's health clinics.

Category
Hormonal Support
Demand
High
Route
Subcutaneous injection
FDA status
Available through compounding pharmacies; previously FDA-approved as Factrel for diagnostic use
Also known as
GnRHGonadotropin-Releasing HormoneFactrel

How Gonadorelin Works

Gonadorelin binds to GnRH receptors on anterior pituitary gonadotroph cells, triggering the release of stored LH and FSH into systemic circulation [1]. Pulsatile exposure maintains receptor sensitivity and sustained gonadotropin secretion, while continuous exposure causes receptor downregulation and paradoxical suppression [2]. This pulsatile signaling preserves the full hypothalamic-pituitary-gonadal axis.

Clinical Evidence

Gonadorelin was originally FDA-approved (as Factrel) for diagnostic assessment of pituitary gonadotropin reserve [1]. Clinical experience in men's health practices since 2020 demonstrates efficacy for maintaining LH, FSH, and testicular volume during TRT [3], though large randomized controlled trials specific to this indication are limited. It emerged as the primary HCG alternative after FDA biologics reclassification restricted compounding access [4].

Clinical Uses

  • Fertility preservation during testosterone replacement therapy
  • Testicular function and volume maintenance on TRT
  • Endogenous LH and FSH stimulation
  • Hypogonadism support (stimulating natural hormone production)
  • Alternative to HCG in testosterone therapy protocols

Patient Selection and Screening

Appropriate for men on TRT who require fertility preservation or testicular volume maintenance, particularly after HCG became difficult to source following the 2020 biologics reclassification [4]. Patients must have intact pituitary function (not appropriate for panhypopituitarism) [1]. Compliance-sensitive patients may struggle with the every-other-day injection schedule; counsel accordingly [2].

Dosing and Administration

Standard protocol is 100-200mcg subcutaneously every other day [1]. Some clinicians prefer 50-100mcg daily for more consistent pulsatile stimulation. Verify efficacy with LH and FSH levels at 4-6 weeks; if gonadotropins remain suppressed, increase dose or frequency [3]. Avoid twice-daily dosing as continuous GnRH exposure triggers receptor downregulation and defeats the therapeutic purpose [2].

Route
Subcutaneous injection
Protocol notes
Administered via subcutaneous injection, typically 100-200mcg every other day or 2-3 times weekly. Pulsatile administration mimics natural GnRH release patterns. Some protocols use daily low-dose injections for more physiologic stimulation.

Safety and Monitoring

Potential side effects

  • Injection site reactions (erythema, swelling, pruritus)
  • Headache (commonly reported, typically transient)
  • Nausea at higher doses
  • Flushing and lightheadedness immediately post-injection
  • Paradoxical gonadotropin suppression if dosing frequency is too high (continuous exposure)

Clinical considerations

  • Requires more frequent dosing than HCG (every other day vs 2-3 times weekly for HCG)
  • Pulsatile administration is important; continuous exposure can paradoxically suppress gonadotropins (downregulation)
  • Emerged as primary HCG alternative after FDA biologics reclassification restricted HCG compounding
  • Monitor LH, FSH, testosterone, and semen analysis to confirm response
  • Patient compliance may be lower due to injection frequency; set expectations during counseling

Practice Economics

Gonadorelin has become a high-volume staple in men's health clinics since 2020, filling the gap left by HCG compounding restrictions [4]. Its every-other-day dosing creates strong recurring prescription revenue with high patient retention [3]. Practices that transitioned their HCG patients to gonadorelin quickly retained patient volume during the supply disruption. Low cost of goods supports healthy margins.

FDA Category Status

Available through compounding pharmacies; previously FDA-approved as Factrel for diagnostic use

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

How does gonadorelin compare to HCG for fertility preservation during TRT?

HCG directly stimulates Leydig cells (LH mimetic), while gonadorelin stimulates the pituitary to release endogenous LH and FSH. Gonadorelin is more physiologic (preserves the full HPG axis) and provides both LH and FSH stimulation, potentially better supporting spermatogenesis. However, it requires more frequent dosing and response can be variable. Gonadorelin became the primary alternative after FDA restrictions limited HCG compounding availability.

Why does gonadorelin require more frequent dosing than HCG?

Gonadorelin has a very short half-life (2-4 minutes for the native peptide, slightly longer for synthetic analogs). It must be administered in a pulsatile pattern to avoid receptor downregulation. Continuous or overly frequent GnRH exposure paradoxically suppresses gonadotropins (the principle behind GnRH agonist suppression in prostate cancer). Every-other-day dosing provides adequate pulsatile stimulation without downregulation.

How do you monitor whether gonadorelin is effective for a patient on TRT?

Key markers include LH and FSH levels (should remain detectable, indicating pituitary response), testicular volume (assess for atrophy prevention), semen analysis (if fertility is the goal), and intratesticular testosterone (if available). If LH/FSH remain suppressed despite gonadorelin, the dose or frequency may need adjustment, or the patient may require addition of HMG for direct gonadal stimulation.

References

  1. Factrel (gonadorelin) FDA prescribing information for diagnostic use
  2. Belchetz et al. - Hypophysial responses to continuous and intermittent GnRH delivery (1978)
  3. Kohn et al. - Age and duration of testosterone therapy predict sperm return after TRT discontinuation (2017)
  4. FDA BPCI Act - Impact on HCG compounding and alternatives

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs